Alto Neuroscience (NYSE:ANRO) Raised to “Sell” at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research analysts also recently issued reports on ANRO. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. BTIG Research raised their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday. Robert W. Baird lowered their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Zacks Research downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.62.

Alto Neuroscience Price Performance

NYSE ANRO opened at $32.14 on Friday. The company has a market capitalization of $1.13 billion, a PE ratio of -13.28 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The business’s fifty day moving average is $25.97 and its 200 day moving average is $22.79. Alto Neuroscience has a fifty-two week low of $3.05 and a fifty-two week high of $33.67.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. Sell-side analysts predict that Alto Neuroscience will post -3 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently made changes to their positions in the business. Torren Management LLC purchased a new stake in shares of Alto Neuroscience during the fourth quarter worth about $62,000. GK Wealth Management LLC purchased a new position in Alto Neuroscience in the 2nd quarter worth approximately $226,000. Balyasny Asset Management L.P. purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $198,000. OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience in the 4th quarter worth approximately $221,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Alto Neuroscience in the 4th quarter worth approximately $304,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.